{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:27:17Z","timestamp":1792459637008,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T00:00:00Z","timestamp":1465171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T00:00:00Z","timestamp":1465171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1038\/nbt.3584","type":"journal-article","created":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T13:30:21Z","timestamp":1465219821000},"page":"738-745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":216,"title":["Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin"],"prefix":"10.1038","volume":"34","author":[{"given":"Rahul","family":"Palchaudhuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Saez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hoggatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Schajnovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany A","family":"Tate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Czechowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youmna","family":"Kfoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Ruchika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick J","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L","family":"Verdine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T","family":"Scadden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,6]]},"reference":[{"key":"BFnbt3584_CR1","unstructured":"Stranges, E., Russo, C.A. & Friedman, B. in Healthcare Cost and Utilization Project (HCUP) Statistical Briefs (Agency for Healthcare Research and Quality (AHRQ), Rockville (MD), 2006)."},{"key":"BFnbt3584_CR2","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1182\/asheducation-2006.1.398","volume":"2006","author":"F Locatelli","year":"2006","unstructured":"Locatelli, F. Reduced-intensity regimens in allogeneic hematopoietic stem cell transplantation for hemoglobinopathies. Hematology 2006, 398\u2013401 (2006).","journal-title":"Hematology"},{"key":"BFnbt3584_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/sj.bmt.1702151","volume":"25","author":"M Andreani","year":"2000","unstructured":"Andreani, M. et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant. 25, 401\u2013404 (2000).","journal-title":"Bone Marrow Transplant."},{"key":"BFnbt3584_CR4","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1182\/blood.V87.8.3494.bloodjournal8783494","volume":"87","author":"M Andreani","year":"1996","unstructured":"Andreani, M. et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 87, 3494\u20133499 (1996).","journal-title":"Blood"},{"key":"BFnbt3584_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1053\/bbmt.2001.v7.pm11787529","volume":"7","author":"MC Walters","year":"2001","unstructured":"Walters, M.C. et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol. Blood Marrow Transplant. 7, 665\u2013673 (2001).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"BFnbt3584_CR6","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","volume":"361","author":"MM Hsieh","year":"2009","unstructured":"Hsieh, M.M. et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N. Engl. J. Med. 361, 2309\u20132317 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnbt3584_CR7","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1182\/blood-2015-02-626002","volume":"125","author":"ML MacMillan","year":"2015","unstructured":"MacMillan, M.L. et al. Alternative donor hematopoietic cell transplantation for Fanconi anemia. Blood 125, 3798\u20133804 (2015).","journal-title":"Blood"},{"key":"BFnbt3584_CR8","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1097\/MPH.0000000000000352","volume":"37","author":"SZ Rousso","year":"2015","unstructured":"Rousso, S.Z. et al. Hematopoietic stem cell transplantations for primary immune deficiencies: 3 decades of experience from a tertiary medical center. J. Pediatr. Hematol. Oncol. 37, e295\u2013e300 (2015).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"BFnbt3584_CR9","doi-asserted-by":"publisher","first-page":"1233158","DOI":"10.1126\/science.1233158","volume":"341","author":"A Biffi","year":"2013","unstructured":"Biffi, A. et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158 (2013).","journal-title":"Science"},{"key":"BFnbt3584_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/MOH.0b013e328365a13b","volume":"20","author":"AJ Worth","year":"2013","unstructured":"Worth, A.J., Booth, C. & Veys, P. Stem cell transplantation for primary immune deficiency. Curr. Opin. Hematol. 20, 501\u2013508 (2013).","journal-title":"Curr. Opin. Hematol."},{"key":"BFnbt3584_CR11","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.2337\/db14-0295","volume":"63","author":"F D'Addio","year":"2014","unstructured":"D'Addio, F. et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis. Diabetes 63, 3041\u20133046 (2014).","journal-title":"Diabetes"},{"key":"BFnbt3584_CR12","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G H\u00fctter","year":"2009","unstructured":"H\u00fctter, G. et al. Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692\u2013698 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnbt3584_CR13","doi-asserted-by":"publisher","first-page":"124ra28","DOI":"10.1126\/scitranslmed.3003509","volume":"4","author":"J Leventhal","year":"2012","unstructured":"Leventhal, J. et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci. Transl. Med. 4, 124ra28 (2012).","journal-title":"Sci. Transl. Med."},{"key":"BFnbt3584_CR14","first-page":"471","volume":"10","author":"N Cartier","year":"2008","unstructured":"Cartier, N. & Aubourg, P. Hematopoietic stem cell gene therapy in Hurler syndrome, globoid cell leukodystrophy, metachromatic leukodystrophy and X-adrenoleukodystrophy. Curr. Opin. Mol. Ther. 10, 471\u2013478 (2008).","journal-title":"Curr. Opin. Mol. Ther."},{"key":"BFnbt3584_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.molmed.2016.02.002","volume":"22","author":"C, Booth","year":"2016","unstructured":"Booth, C., Gaspar, H.B. & Thrasher, A.J. Treating Immunodeficiency through HSC Gene Therapy. Trends Mol. Med. 22, 317\u2013327 (2016).","journal-title":"Trends Mol. Med."},{"issue":"suppl. 2","key":"BFnbt3584_CR16","doi-asserted-by":"publisher","first-page":"S318","DOI":"10.1086\/513852","volume":"179","author":"HL Malech","year":"1999","unstructured":"Malech, H.L. Progress in gene therapy for chronic granulomatous disease. J. Infect. Dis. 179, (suppl. 2), S318\u2013S325 (1999).","journal-title":"J. Infect. Dis."},{"key":"BFnbt3584_CR17","first-page":"S27","volume":"57","author":"HL Malech","year":"2004","unstructured":"Malech, H.L., Choi, U. & Brenner, S. Progress toward effective gene therapy for chronic granulomatous disease. Jpn. J. Infect. Dis. 57, S27\u2013S28 (2004).","journal-title":"Jpn. J. Infect. Dis."},{"key":"BFnbt3584_CR18","doi-asserted-by":"publisher","first-page":"1233151","DOI":"10.1126\/science.1233151","volume":"341","author":"A Aiuti","year":"2013","unstructured":"Aiuti, A. et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151 (2013).","journal-title":"Science"},{"key":"BFnbt3584_CR19","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar, J.M. et al. Autologous hematopoietic stem cell transplantation vs. intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. J. Am. Med. Assoc. 311, 2490\u20132498 (2014).","journal-title":"J. Am. Med. Assoc."},{"key":"BFnbt3584_CR20","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1182\/asheducation-2009.1.690","volume":"2009","author":"DA Persons","year":"2009","unstructured":"Persons, D.A. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders. Hematology (Am. Soc. Hematol. Educ. Program) 2009, 690\u2013697 (2009).","journal-title":"Hematology (Am. Soc. Hematol. Educ. Program)"},{"key":"BFnbt3584_CR21","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1182\/blood.V124.21.4797.4797","volume":"124","author":"M Cavazzana","year":"2014","unstructured":"Cavazzana, M. et al. Study Hgb-205: outcomes of gene therapy for hemoglobinopathies via transplantation of autologous hematopoietic stem cells transduced ex vivo with a lentiviral \u03b2A\u2013T87Q\u2013globin vector (LentiGlobin\u00ae BB305 Drug Product). Blood 124, 4797 (2014).","journal-title":"Blood"},{"key":"BFnbt3584_CR22","unstructured":"Hoffman, R. Hematology: Basic Principles and Practice 5th edn. (Churchill Livingstone\/Elsevier, Philadelphia, PA, 2009)."},{"key":"BFnbt3584_CR23","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/sj.bmt.1705173","volume":"36","author":"G La Nasa","year":"2005","unstructured":"La Nasa, G. et al. Unrelated donor stem cell transplantation in adult patients with thalassemia. Bone Marrow Transplant. 36, 971\u2013975 (2005).","journal-title":"Bone Marrow Transplant."},{"key":"BFnbt3584_CR24","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1182\/blood-2005-09-3593","volume":"107","author":"J Chen","year":"2006","unstructured":"Chen, J. et al. Mobilization as a preparative regimen for hematopoietic stem cell transplantation. Blood 107, 3764\u20133771 (2006).","journal-title":"Blood"},{"key":"BFnbt3584_CR25","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1126\/science.1149726","volume":"318","author":"A Czechowicz","year":"2007","unstructured":"Czechowicz, A., Kraft, D., Weissman, I.L. & Bhattacharya, D. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 318, 1296\u20131299 (2007).","journal-title":"Science"},{"key":"BFnbt3584_CR26","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1182\/blood-2010-07-295949","volume":"116","author":"X Xue","year":"2010","unstructured":"Xue, X. et al. Antibody targeting KIT as pretransplantation conditioning in immunocompetent mice. Blood 116, 5419\u20135422 (2010).","journal-title":"Blood"},{"key":"BFnbt3584_CR27","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1182\/blood-2009-10-248898","volume":"115","author":"NM Fewkes","year":"2010","unstructured":"Fewkes, N.M. et al. Pharmacologic modulation of niche accessibility via tyrosine kinase inhibition enhances marrow and thymic engraftment after hematopoietic stem cell transplantation. Blood 115, 4120\u20134129 (2010).","journal-title":"Blood"},{"key":"BFnbt3584_CR28","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1046\/j.1365-2141.1996.d01-1730.x","volume":"93","author":"G Bergamaschi","year":"1996","unstructured":"Bergamaschi, G. et al. Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. Br. J. Haematol. 93, 789\u2013794 (1996).","journal-title":"Br. J. Haematol."},{"key":"BFnbt3584_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1440-1711.2005.01360.x","volume":"83","author":"G Pietersz","year":"2005","unstructured":"Pietersz, G. Cytotoxins and immunotoxins for cancer therapy: clinical applications. Immunol. Cell Biol. 83, 450 (2005).","journal-title":"Immunol. Cell Biol."},{"key":"BFnbt3584_CR30","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc1891","volume":"6","author":"I Pastan","year":"2006","unstructured":"Pastan, I., Hassan, R., Fitzgerald, D.J. & Kreitman, R.J. Immunotoxin therapy of cancer. Nat. Rev. Cancer 6, 559\u2013565 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnbt3584_CR31","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","volume":"98","author":"L Luznik","year":"2001","unstructured":"Luznik, L., Jalla, S., Engstrom, L.W., Iannone, R. & Fuchs, E.J. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 98, 3456\u20133464 (2001).","journal-title":"Blood"},{"key":"BFnbt3584_CR32","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1182\/blood-2014-08-593426","volume":"124","author":"B Saez","year":"2014","unstructured":"Saez, B. et al. Inhibiting stromal cell heparan sulfate synthesis improves stem cell mobilization and enables engraftment without cytotoxic conditioning. Blood 124, 2937\u20132947 (2014).","journal-title":"Blood"},{"key":"BFnbt3584_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/sj.leu.2403268","volume":"18","author":"GA Colvin","year":"2004","unstructured":"Colvin, G.A. et al. Murine marrow cellularity and the concept of stem cell competition: geographic and quantitative determinants in stem cell biology. Leukemia 18, 575\u2013583 (2004).","journal-title":"Leukemia"},{"key":"BFnbt3584_CR34","unstructured":"Ignatavicus, D.D. & Workman, M.L. Medical-Surgical Nursing: Patient-Centered Collaborative Care 6th edn. (Saunders Elsevier, St. Louis, MO, 2010)."},{"key":"BFnbt3584_CR35","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1182\/blood-2008-10-183459","volume":"114","author":"M Dominici","year":"2009","unstructured":"Dominici, M. et al. Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation. Blood 114, 2333\u20132343 (2009).","journal-title":"Blood"},{"key":"BFnbt3584_CR36","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1752-8062.2009.00128.x","volume":"2","author":"KM Williams","year":"2009","unstructured":"Williams, K.M. et al. Single cell analysis of complex thymus stromal cell populations: rapid thymic epithelia preparation characterizes radiation injury. Clin. Transl. Sci. 2, 279\u2013285 (2009).","journal-title":"Clin. Transl. Sci."},{"key":"BFnbt3584_CR37","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1126\/science.2154033","volume":"247","author":"TM Ryan","year":"1990","unstructured":"Ryan, T.M. et al. Human sickle hemoglobin in transgenic mice. Science 247, 566\u2013568 (1990).","journal-title":"Science"},{"key":"BFnbt3584_CR38","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1182\/blood.V97.12.3960","volume":"97","author":"R Iannone","year":"2001","unstructured":"Iannone, R. et al. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia. Blood 97, 3960\u20133965 (2001).","journal-title":"Blood"},{"key":"BFnbt3584_CR39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s15010-011-0229-y","volume":"40","author":"M Mikulska","year":"2012","unstructured":"Mikulska, M. et al. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients. Infection 40, 271\u2013278 (2012).","journal-title":"Infection"},{"key":"BFnbt3584_CR40","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/asheducation.V2012.1.265.3800160","volume":"2012","author":"KA Marr","year":"2012","unstructured":"Marr, K.A. Delayed opportunistic infections in hematopoietic stem cell transplantation patients: a surmountable challenge. Hematology (Am. Soc. Hematol. Educ. Program) 2012, 265\u2013270 (2012).","journal-title":"Hematology (Am. Soc. Hematol. Educ. Program)"},{"key":"BFnbt3584_CR41","first-page":"4963","volume":"104","author":"DL Kraft","year":"2004","unstructured":"Kraft, D.L. & Weissman, I.L. Effect and kinetics of depleting ACK--2 Anti C- Kit monoclonal antibody on hematopoeisis and hematopoetic progenitors and ability to condition for bone marrow transplantation. ASH Annual Meeting Abstracts 104, 4963 (2004).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"BFnbt3584_CR42","first-page":"278","volume":"5","author":"SC Derderian","year":"2014","unstructured":"Derderian, S.C., Jeanty, C., Walters, M.C., Vichinsky, E. & MacKenzie, T.C. In utero hematopoietic cell transplantation for hemoglobinopathies. Front. Pharmacol. 5, 278 (2014).","journal-title":"Front. Pharmacol."},{"key":"BFnbt3584_CR43","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1089\/hum.2014.031","volume":"25","author":"D Chandrasekaran","year":"2014","unstructured":"Chandrasekaran, D., Nakamoto, B., Watts, K.L., Kiem, H.P. & Papayannopoulou, T. Modeling promising nonmyeloablative conditioning regimens in nonhuman primates. Hum. Gene Ther. 25, 1013\u20131022 (2014).","journal-title":"Hum. Gene Ther."},{"key":"BFnbt3584_CR44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.pai.0000173054.83414.22","volume":"13","author":"M Miettinen","year":"2005","unstructured":"Miettinen, M. & Lasota, J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl. Immunohistochem. Mol. Morphol. 13, 205\u2013220 (2005).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"BFnbt3584_CR45","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/1042819031000151932","volume":"45","author":"MH Dahlke","year":"2004","unstructured":"Dahlke, M.H., Larsen, S.R., Rasko, J.E. & Schlitt, H.J. The biology of CD45 and its use as a therapeutic target. Leuk. Lymphoma 45, 229\u2013236 (2004).","journal-title":"Leuk. Lymphoma"},{"key":"BFnbt3584_CR46","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1182\/blood-2011-09-380436","volume":"119","author":"Y Chen","year":"2012","unstructured":"Chen, Y. et al. Durable donor engraftment after radioimmunotherapy using \u03b1-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. Blood 119, 1130\u20131138 (2012).","journal-title":"Blood"},{"key":"BFnbt3584_CR47","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1182\/blood-2005-06-2317","volume":"107","author":"JM Pagel","year":"2006","unstructured":"Pagel, J.M. et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107, 2184\u20132191 (2006).","journal-title":"Blood"},{"key":"BFnbt3584_CR48","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1749-6632.2003.tb03236.x","volume":"996","author":"MK Brenner","year":"2003","unstructured":"Brenner, M.K. et al. Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man. Ann. NY Acad. Sci. 996, 80\u201388 (2003).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnbt3584_CR49","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1182\/blood-2002-08-2379","volume":"101","author":"GG Wulf","year":"2003","unstructured":"Wulf, G.G., Luo, K.L., Goodell, M.A. & Brenner, M.K. Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation. Blood 101, 2434\u20132439 (2003).","journal-title":"Blood"},{"key":"BFnbt3584_CR50","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/S0140-6736(09)60945-4","volume":"374","author":"KC Straathof","year":"2009","unstructured":"Straathof, K.C. et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1\/2 study. Lancet 374, 912\u2013920 (2009).","journal-title":"Lancet"},{"issue":"suppl. 2","key":"BFnbt3584_CR51","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1038\/bmt.2008.284","volume":"42","author":"JH Dalle","year":"2008","unstructured":"Dalle, J.H. HSCT for Fanconi anemia in children: factors that influence early and late results. Bone Marrow Transplant. 42 (suppl. 2), S51\u2013S53 (2008).","journal-title":"Bone Marrow Transplant."},{"key":"BFnbt3584_CR52","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1242\/dev.106575","volume":"141","author":"A Nakamura-Ishizu","year":"2014","unstructured":"Nakamura-Ishizu, A., Takizawa, H. & Suda, T. The analysis, roles and regulation of quiescence in hematopoietic stem cells. Development 141, 4656\u20134666 (2014).","journal-title":"Development"},{"key":"BFnbt3584_CR53","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/(SICI)1097-0045(19980301)34:4<259::AID-PROS3>3.0.CO;2-C","volume":"34","author":"R Rodriguez","year":"1998","unstructured":"Rodriguez, R., Lim, H.Y., Bartkowski, L.M. & Simons, J.W. Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics. Prostate 34, 259\u2013269 (1998).","journal-title":"Prostate"},{"key":"BFnbt3584_CR54","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1016\/j.bmcl.2014.10.021","volume":"24","author":"H Bouchard","year":"2014","unstructured":"Bouchard, H., Viskov, C. & Garcia-Echeverria, C. Antibody-drug conjugates\u2014a new wave of cancer drugs. Bioorg. Med. Chem. Lett. 24, 5357\u20135363 (2014).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnbt3584_CR55","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1182\/blood.V83.5.1390.1390","volume":"83","author":"OW Press","year":"1994","unstructured":"Press, O.W., Howell-Clark, J., Anderson, S. & Bernstein, I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 83, 1390\u20131397 (1994).","journal-title":"Blood"},{"key":"BFnbt3584_CR56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0022-1759(02)00094-7","volume":"266","author":"A Bikoue","year":"2002","unstructured":"Bikoue, A., Janossy, G. & Barnett, D. Stabilised cellular immuno-fluorescence assay: CD45 expression as a calibration standard for human leukocytes. J. Immunol. Methods 266, 19\u201332 (2002).","journal-title":"J. Immunol. Methods"},{"key":"BFnbt3584_CR57","first-page":"25","volume":"11","author":"UH Weidle","year":"2014","unstructured":"Weidle, U.H. et al. Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer. Cancer Genomics Proteomics 11, 25\u201338 (2014).","journal-title":"Cancer Genomics Proteomics"},{"key":"BFnbt3584_CR58","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1182\/blood-2008-03-145946","volume":"112","author":"Q Jiang","year":"2008","unstructured":"Jiang, Q. et al. FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2\u2212\/\u2212gammaC\u2212\/\u2212 mice in vivo. Blood 112, 2858\u20132868 (2008).","journal-title":"Blood"},{"key":"BFnbt3584_CR59","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1084\/jem.157.4.1077","volume":"157","author":"H, Yakura","year":"1983","unstructured":"Yakura, H., Shen, F.W., Bourcet, E. & Boyse, E.A. On the function of Ly-5 in the regulation of antigen-driven B cell differentiation. Comparison and contrast with Lyb-2. J. Exp. Med. 157, 1077\u20131088 (1983).","journal-title":"J. Exp. Med."},{"key":"BFnbt3584_CR60","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1182\/blood-2005-04-1658","volume":"106","author":"W Jia","year":"2005","unstructured":"Jia, W. Li, W. & He, Y.-W. The extracellular matrix protein mindin serves as an integrin ligand and is critical for inflammatory cell recruitment. Blood 106, 3854\u20133859 (2005).","journal-title":"Blood"},{"key":"BFnbt3584_CR61","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.4049\/jimmunol.0901361","volume":"183","author":"M Fedeli","year":"2009","unstructured":"Fedeli, M. et al. Dicer-dependent microRNA pathway controls invariant NKT cell development. J. Immunol. 183, 2506\u20132512 (2009).","journal-title":"J. Immunol."},{"key":"BFnbt3584_CR62","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jim.2007.08.004","volume":"328","author":"T Kamala","year":"2007","unstructured":"Kamala, T. Hock immunization: a humane alternative to mouse footpad injections. J. Immunol. Methods. 328, 204\u2013214 (2007).","journal-title":"J. Immunol. Methods."},{"key":"BFnbt3584_CR63","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1073\/pnas.0609490104","volume":"104","author":"T, Sugiyama","year":"2007","unstructured":"Sugiyama, T., Rodriguez, R.T., McLean, G.W. & Kim, S.K. HConserved markers of fetal pancreatic epithelium permit prospective isolation of islet progenitor cells by FACS. Proc. Natl. Acad. Sci. USA 104, 175\u2013180 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnbt3584_CR64","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/jlb.66.6.996","volume":"66","author":"R Schabath","year":"1999","unstructured":"Schabath, R. et al. The murine chemokine receptor CXCR4 is tightly regulated during T cell development and activation. J. Leukoc. Biol 66, 996\u20131004 (1999).","journal-title":"J. Leukoc. Biol"},{"key":"BFnbt3584_CR65","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/intimm\/12.3.313","volume":"12","author":"M, Ogawa","year":"2000","unstructured":"Ogawa, M., ten Boekel, E. & Melchers, F. Identification of CD19(\u2212)B220(+)c-Kit(+)Flt3\/Flk-2(+)cells as early B lym phoid precursors before pre-B-I cells in juvenile mouse bone marrow. Int. Immunol 12, 313\u2013324 (2000).","journal-title":"Int. Immunol"},{"key":"BFnbt3584_CR66","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1158\/1078-0432.CCR-13-0839","volume":"20","author":"J Dai","year":"2014","unstructured":"Dai, J. et al. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin. Cancer Res 20, 617\u2013630 (2014).","journal-title":"Clin. Cancer Res"},{"key":"BFnbt3584_CR67","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00262-008-0518-1","volume":"57","author":"MM Schmidt","year":"2008","unstructured":"Schmidt, M.M., Thurber, G.M. & Wittrup, K.D. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol. Immunother. 57, 1879\u20131890 (2008).","journal-title":"Cancer Immunol. Immunother."},{"key":"BFnbt3584_CR68","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature07434","volume":"457","author":"C Lo Celso","year":"2009","unstructured":"Lo Celso, C. et al. Live-animal tracking of individual haematopoietic stem\/progenitor cells in their niche. Nature 457, 92\u201396 (2009).","journal-title":"Nature"},{"key":"BFnbt3584_CR69","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-1-62703-290-2_12","volume":"979","author":"HE Lynch","year":"2013","unstructured":"Lynch, H.E. & Sempowski, G.D. Molecular measurement of T cell receptor excision circles. Methods Mol. Biol. 979, 147\u2013159 (2013).","journal-title":"Methods Mol. Biol."}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nbt.3584.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nbt.3584","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nbt.3584.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T22:13:25Z","timestamp":1650147205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nbt.3584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,6]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["BFnbt3584"],"URL":"https:\/\/doi.org\/10.1038\/nbt.3584","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726406351.793522495","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.726406351.793527171","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.726406351.793521995","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.726406351.793568486","asserted-by":"object"}]},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,6]]},"assertion":[{"value":"16 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare relevant competing financial interests as follows. Magenta Therapeutics, equity and consulting: R.P., J.H., A.C., D.J.R., and D.T.S. Fate Therapeutics, equity and consulting: D.T.S.; consulting: J.H. GlaxoSmithKline, consulting and sponsored research: J.H. and D.T.S. Intellia Therapeutics, equity and consulting: D.J.R. Moderna Therapeutics, equity: D.J.R. Inventors, US patent applications (US 62\/143,642; US 62\/220,204; US 62\/221,595; and US 62\/239,573): R.P. and D.T.S.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}